Zimmer Biomet’s flagship robot, Rosa, is expected to make gains in the near future, CEO Ivan Tornos said at the Barclays 27th Annual Global Healthcare Conference. Mr. Tornos said adoption of the robot ...
The ROSA Shoulder robotic application has received positive feedback, indicating strong potential for long-term growth in the robotics-assisted surgery segment. Additionally, Zimmer Biomet has ...
Hosted on MSN29d
NeuroOne projects FY 2025 revenue growth of up to 190% with Zimmer Biomet partnershipGross margins are projected to range from 47% to 51%, benefiting from improved transfer pricing under the Zimmer Biomet partnership. Rosa stated that the company is on track to submit a 510(k ...
Equities researchers at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for Zimmer Biomet in a report ...
In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research Report).
This was the stock's second consecutive day of losses.
Zimmer Biomet (NYSE: ZBH) announced today that it received FDA 510(k) clearance for its Persona Revision SoluTion Femur.
WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA ...
The stock's fall snapped a four-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback